TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma

This study compares two chemotherapy drugs — idarubicin and doxorubicin — used in a procedure called TACE (transarterial chemoembolization), which delivers chemotherapy directly to liver tumors while cutting off their blood supply. Researchers want to see which drug works better for liver cancer. **You may be eligible if:** - You are 19 or older - You have been diagnosed with hepatocellular carcinoma (HCC), the most common type of liver cancer - You have 5 or fewer tumors, with the largest being 5 cm or smaller - You have not previously been treated for HCC - Your liver is still functioning reasonably well (Child-Pugh class A or B) - Your overall health is reasonably good (ECOG 0-2) **You may NOT be eligible if:** - You have already received treatment for liver cancer - You have more than 5 tumors or a tumor larger than 5 cm - You have severe liver, kidney, or heart problems - You have cancer that has spread outside the liver Talk to your doctor to see if this trial is right for you.